Recombinant Mouse Anti-MUC1 Antibody scFv Fragment (CTM01) (CAT#: PABX-183-S (P))

Figure 1 In Vitro Cytotoxicity of CTM01 Carbohydrate and Amide Conjugates

Hamann, P. R., Hinman, L. M., Beyer, C. F., Greenberger, L. M., Lin, C., Lindh, D., ... & Upeslacis, J. (2005). An anti-MUC1 antibody− calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjugate chemistry, 16(2), 346-353.

Figure 2 Time-course of the response of Lu-78 xenograft tumors to the CTM01 amide conjugate, to a similar control conjugate made with the nonbinding MOPC-21 antibody, and to treatment with a representative calicheamicin derivative alone.

Athymic mice were implanted sc with Lu-78 cells and then dosed when tumors were approximately 50 mg in size. The doses indicated were given on days 14, 18, and 22, as indicated by the arrows, and are given in calicheamicin equivalents. The corresponding concentration of antibody is 40-fold greater. There were no deaths in any group, except for one with NAc-gamma calicheamicin. Error bars are SEMs and were omitted for NAc-gamma calicheamicin (dosed at the MTD) for clarity.

Hamann, P. R., Hinman, L. M., Beyer, C. F., Greenberger, L. M., Lin, C., Lindh, D., ... & Upeslacis, J. (2005). An anti-MUC1 antibody− calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjugate chemistry, 16(2), 346-353.

Figure 3 Competitive radioimmunoassay for mCTM01 and hCTM01.

Affinity of the humanized antibody relative to the murine antibody is 1.3.

Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Shochat, D., & Mountain, A. (2005). A Calicheamicin Conjugate with a Fully Humanized Anti-MUC1 Antibody Shows Potent Antitumor Effects in Breast and Ovarian Tumor Xenografts. Bioconjugate Chemistry, 16(2), 354–360.